Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung

[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.10.3322/caac.2116623335087Search in Google Scholar

[2] Stella GM, Scabini R, Inghilleri S, et al. EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. J Cancer Res Clin Oncol. May 5 2013.10.1007/s00432-013-1444-y23644698Search in Google Scholar

[3] Yasuda H, Park E, Yun CH, et al: Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. Sci Transl Med. 2013;5: 216ra177.10.1126/scitranslmed.3007205395477524353160Search in Google Scholar

[4] Goodin S. Erlotinib: Optimizing therapy with predictors of response? Clin Cancer Res 2006;12:2961-2963.10.1158/1078-0432.CCR-06-042616707589Search in Google Scholar

[5] Ji H, Li D, Chen L, Shimamura T, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFRtargeted therapies. Cancer Cell 2006;9:485-95.10.1016/j.ccr.2006.04.02216730237Search in Google Scholar

[6] Lee, C.K., Brown, C., Gralla, R.J., et al. (2013) Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. Journal of the National Cancer Institute, 105, 595-605. http://dx.doi.org/10.1093/jnci/djt072.10.1093/jnci/djt07223594426Search in Google Scholar

[7] Lee, C.K., Brown, C., Gralla, R.J., et al. (2013) Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. Journal of the National Cancer Institute, 105, 595-605. http://dx.doi.org/10.1093/jnci/djt07210.1093/jnci/djt072Search in Google Scholar

[8] Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4ALK fusion gene in nonsmall- cell lung cancer. Nature 2007; 448:561-6.10.1038/nature0594517625570Search in Google Scholar

[9] Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther. 2001;5:471-85.Search in Google Scholar

[10] Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190-1203.10.1016/j.cell.2007.11.02518083107Search in Google Scholar

[11] Thunnissen E, Bubendorf L, Manfred D, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012;461:245-57.10.1007/s00428-012-1281-4343221422825000Search in Google Scholar

[12] Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-33.10.1002/cncr.2418119170230Search in Google Scholar

[13] Lindeman NI, Cagle PT, Beasley MB, et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology. 2013; 8(7):823-859.10.1097/JTO.0b013e318290868f415996023552377Search in Google Scholar

[14] Anuradha Ch, Kumar P, Vanita N, et al. Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity. PLOS ONE, October 2013;8(10):e76164 www.plosone.org.10.1371/journal.pone.0076164379070624124538Search in Google Scholar

[15] Hassan E, Hanane In, Anouar B, et al. Frequency and Type of Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma. Journal of Thoracic Oncology, September 2013;8:9.Search in Google Scholar

[16] Sharma S, Bell D, Settleman J, and Haber D. Epidermal Growth Factor Mutation in Lung Cancer. Nature Reviews Cancer, 2007; 7: 169-181. http://dx.doi.org/10.1038/nrc2088.10.1038/nrc208817318210Search in Google Scholar

[17] Nabil Ismaili and Rizlane Belbaraka. Spectrum of EGFR Mutation in Lung Adenocarcinoma in Morocco. Journal of Thoracic Oncology Volume 8, Number 12, December 2013.10.1097/JTO.000000000000001424389449Search in Google Scholar

[18] Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361: 947-957.10.1056/NEJMoa081069919692680Search in Google Scholar

[19] Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64: 8919-8923.10.1158/0008-5472.CAN-04-281815604253Search in Google Scholar

[20] Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 2004;10: 8195-8203.10.1158/1078-0432.CCR-04-124515623594Search in Google Scholar

[21] Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118: 257-62.10.1002/ijc.2149616231326Search in Google Scholar

[22] Lee YJ, Cho BC, Jee SH, et al. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol 2010;28:487-92.10.1200/JCO.2009.24.548020008630Search in Google Scholar

[23] Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-smallcell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27:424710.1200/JCO.2009.22.6993274426819667264Search in Google Scholar